TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting

BACKGROUND: We investigated the impact of PIK3CA and TP53 mutations and p53 protein status on the outcome of patients who had been treated with adjuvant anthracycline-taxane chemotherapy within clinical trials in the pre- and post-trastuzumab era. RESULTS: TP53 and PIK3CA mutations were found in 380...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncotarget
Prif Awduron: Fountzilas, George, Giannoulatou, Eleni, Alexopoulou, Zoi, Zagouri, Flora, Timotheadou, Eleni, Papadopoulou, Kyriaki, Lakis, Sotiris, Bobos, Mattheos, Poulios, Christos, Sotiropoulou, Maria, Lyberopoulou, Aggeliki, Gogas, Helen, Pentheroudakis, George, Pectasides, Dimitrios, Koutras, Angelos, Christodoulou, Christos, Papandreou, Christos, Samantas, Epaminontas, Papakostas, Pavlos, Kosmidis, Paris, Bafaloukos, Dimitrios, Karanikiotis, Charisios, Dimopoulos, Meletios-Athanassios, Kotoula, Vassiliki
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Impact Journals LLC 2016
Pynciau:
Research Paper
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5078047/
https://ncbi.nlm.nih.gov/pubmed/27129168
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.9022
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg